Received May 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | U7947AA | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | 2088619 | OT |
patient was administered ROTATEQ & VAXELIS during a temperature excursion.; No additional AE reported.; This spontaneous report was received from an office manager concerning to a patient of unknown age and gender. The patient's medical history, historical drugs, known drug allergies, concurrent conditions, and concomitant therapies were not reported. On 24-Apr-2025, the patient was vaccinated with Rotavirus Vaccine, Live, Oral, Pentavalent (Rotateq), Oral solution (lot #2088619, expiration date: 09-Mar-2026) 1 dosage form (1 dose), administered by Oral route and with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, ... (VAXELIS), Suspension for injection (lot #U7947AA, expiration date: 20-Oct-2026) 1 dosage form (1 dose; strength 0.5 mL) (route of administration not reported), both as Prophylaxis. However, the reporter stated that these doses underwent a temperature excursion at 0°C for 1 hour, no previous excursions had occurred, no additional events or details reported.; Reporter's Comments: